➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Medtronic
Dow
McKesson
Johnson and Johnson

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR XELJANZ XR

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Xeljanz Xr

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01932372 ↗ Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis Active, not recruiting Pfizer N/A 2013-07-01 The objective of this Surveillance is to verify the following subject matters concerning Tofacitinib (Xeljanz) under general practice. 1) Occurrence of adverse reactions, factors that may potentially affect safety and efficacy 2) Long-term safety (particularly, malignant tumors and serious infections) and efficacy Occurrences of malignant tumors and serious infections will be compared with a control group.
NCT02157012 ↗ Evaluation of the Condition of Rheumatoid Arthritis After Treatment Recruiting Showa Inan General Hospital Phase 4 2014-05-01 To examine the safety and effectiveness after Xeljanz treatment in rheumatoid arthritis patients
NCT02157012 ↗ Evaluation of the Condition of Rheumatoid Arthritis After Treatment Recruiting Shinshu University Phase 4 2014-05-01 To examine the safety and effectiveness after Xeljanz treatment in rheumatoid arthritis patients
NCT02299297 ↗ An Open-Label Pilot Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis Active, not recruiting Locks of Love Phase 2 2015-01-01 This is an open-label pilot study of tofacitinib taken daily for 6 months in the treatment of moderate to severe AA, and alopecia totalis or universalis, followed by 6 months follow-up off drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment. There will be the option of increasing the treatment duration up to an additional 6 months beyond the initially scheduled 6 months of treatment, if clinically indicated, and at the discretion of the investigator.
NCT02299297 ↗ An Open-Label Pilot Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis Active, not recruiting Julian M. Mackay-Wiggan Phase 2 2015-01-01 This is an open-label pilot study of tofacitinib taken daily for 6 months in the treatment of moderate to severe AA, and alopecia totalis or universalis, followed by 6 months follow-up off drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment. There will be the option of increasing the treatment duration up to an additional 6 months beyond the initially scheduled 6 months of treatment, if clinically indicated, and at the discretion of the investigator.
NCT02996500 ↗ Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate Recruiting Pfizer Phase 2 2016-11-01 This is a Phase 2, multicenter, randomized, double blind, double dummy, placebo and active-controlled, parallel group study to assess the efficacy and safety of PF 06650833 at Week 12 in subjects with moderate-severe, active, RA who have had an inadequate response to MTX. PF-06650833 or matching placebo tablets will be administered orally QD under fasting conditions, and tofacitinib or matching tofacitinib placebo tablets will be administered orally BID for 12 weeks in a blinded fashion.
NCT03000439 ↗ A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA Not yet recruiting Pfizer Phase 3 2017-08-04 A randomized withdrawal study in which responders to open-label treatment with tofacitinib will be randomized in a 1:1 ratio to tofacitinib or placebo in a double-blind phase. In the double-blind phase "time to sJIA flare" will be evaluated as primary endpoint and subjects will be discontinued once they experience sJIA flare. Once 31 flares are reported the study will be completed.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Xeljanz Xr

Condition Name

Condition Name for Xeljanz Xr
Intervention Trials
Rheumatoid Arthritis 7
COVID-19 2
Psoriatic Arthritis 2
Alopecia Areata 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Xeljanz Xr
Intervention Trials
Arthritis 9
Arthritis, Rheumatoid 7
Alopecia 3
Arthritis, Psoriatic 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Xeljanz Xr

Trials by Country

Trials by Country for Xeljanz Xr
Location Trials
United States 8
Sweden 3
China 2
Canada 2
Korea, Republic of 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Xeljanz Xr
Location Trials
Pennsylvania 2
Colorado 1
Oregon 1
California 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Xeljanz Xr

Clinical Trial Phase

Clinical Trial Phase for Xeljanz Xr
Clinical Trial Phase Trials
Phase 4 7
Phase 3 2
Phase 2 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Xeljanz Xr
Clinical Trial Phase Trials
Not yet recruiting 13
Recruiting 7
Active, not recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Xeljanz Xr

Sponsor Name

Sponsor Name for Xeljanz Xr
Sponsor Trials
Pfizer 6
Göteborg University 1
Julian M. Mackay-Wiggan 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Xeljanz Xr
Sponsor Trials
Other 26
Industry 10
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Colorcon
Mallinckrodt
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.